Navigation Links
Lilly Highlights Transformation Strategy for Wall Street, Reviews Robust Pipeline and Sets 2009 Financial Guidance
Date:12/11/2008

    NEW YORK, Dec. 11 /PRNewswire-FirstCall/ --

    -- Innovation and Patient-Centered Approach Expected to Drive Future
       Success
    -- Lilly Climbs into Top 10 Pharmaceutical Companies in Worldwide Sales
       and Is Fastest Growing in U.S.
    -- FIPNet Strategy Expands Global Reach and Improves R&D Productivity
    -- Company Aims to Reduce Cost of Bringing New Medicine to Market from
       $1.2 Billion to $800 Million by 2010.
    -- R&D Pipeline Boasts Unprecedented 59 Molecules in Clinical Development
    -- Investment in Biotechnology Capabilities Results in Expanded Large
       Molecule Portfolio
    -- ImClone Acquisition Creates Leading Oncology Franchise
    -- 2009 EPS Guidance Set at $4.00 to $4.25, Including $.30 to $.35 of
       ImClone Dilution
    -- Excluding ImClone Dilution, 2009 EPS Expected to be $4.35 to $4.55

At its annual meeting with the investment community, Eli Lilly and Company (NYSE: LLY) today highlighted progress on its expanding pipeline of innovative molecules and marketed medicines, provided investors with sales and earnings guidance for 2009, and reviewed the transformation efforts that the company is making to excel in an increasingly challenging healthcare environment.

"Lilly continues to deliver strong financial results to our shareholders through an attractive combination of volume-based sales growth for key marketed products and an ongoing commitment to productivity and cost containment," commented John C. Lechleiter, Ph.D., Lilly's president and chief executive officer. "Our scientists are dedicated to maximizing the potential of our pipeline, which now boasts an unprecedented 59 molecules in clinical development, 40 percent of which are biotech-based. Lilly's success depends on innovation, and the promising molecules we are discussing at today's m
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
2. Lilly Declares Fourth-Quarter Dividend
3. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
6. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
7. Lilly Announces Termination of AIR Insulin Program
8. HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
9. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
10. Lilly Reports Solid First-Quarter Results
11. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015  Ceres, Inc. (Nasdaq: ... a U.S. patent for a genetic sequence derived from ... as research, product development and plant transformation. The company ... biosynthetic processes that are the target of a class ... companies a commercial license to the innovation, including an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals ... focused on discovering and developing innovative therapies primarily ... an update on the status of the Company,s ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... 3,085 and 21 shares of Series A Preferred ...
(Date:5/27/2015)... 27, 2015 ­ Caris Life Sciences®, a ... precision medicine, today announced it has appointed the Levine ... of excellence site in the Caris Centers of Excellence ... Cancer Institute is one of the largest cancer care ... new cancer patients annually. Derek Raghavan , M.D., ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
Breaking Biology Technology:Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 2Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 3Caris Life Sciences Designates Levine Cancer Institute as a Caris Center of Excellence 4Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3
... January 28 The Binding Site Limited,("The Binding ... company, today announces the publication of the first,international ... and management of multiple myeloma, a cancer of ... disorders. , The guidelines ...
... an announcement made recently by Astellas Pharma Inc., CV Therapeutics, ... received a letter dated November 13, 2008 from Astellas setting ... at a price of $16.00 per share, subject to due ... deliberation, with the assistance of its financial and legal advisors, ...
... PTS by Albemarle responds to the demand in ... 27 Leading specialty chemical company, Albemarle Corporation, ... company, Zymes LLC, have joined forces to scale-up ... The next generation technology promotes the clear ...
Cached Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... Bell, PA (January 7, 2013) The PATH Malaria ... MKT: INO) today announced a follow-on collaboration to ... technologies. Researchers will test whether a novel vaccine ... innovative vaccine delivery technology called electroporation could induce ...
... Researchers have identified four new regions on the human ... dangerous condition found predominantly in people with ancestors along ... this 4,000-mile network linking the Far East with Europe ... the Silk Road disease, genes. National Institutes of Health ...
... BOSTON January 8, 2013 -- As part of their ... development of obesity, Joslin Diabetes Center scientists have identified a ... major role in energy metabolism and fat storage. This ... obesity. The study is being published today ahead of print ...
Cached Biology News:MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 2MVI and Inovio partner to develop malaria vaccines using innovative vaccine delivery tech 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 2Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 3Genetic mystery of Behcet's disease unfolds along the ancient Silk Road 4Joslin researchers identify important factor in fat storage and energy metabolism 2